Nevro Posts Q1 Revenue of $87.8M
- ByInvesting.com-
Nevro (NVRO) reported Q1 revenue of $87.8 million versus the consensus estimate of $86.18 million.GUIDANCE:Nevro sees Q2 2022 revenue of $103-106 million, versus the consensus of...
Nevro (NVRO) reported Q1 revenue of $87.8 million versus the consensus estimate of $86.18 million.GUIDANCE:Nevro sees Q2 2022 revenue of $103-106 million, versus the consensus of...
Robert W. Baird analyst Michael Polark reiterated a Hold rating on Nevro Crop (NYSE:NVRO) on Wednesday, setting a price target of $125, which is approximately 4.40% above the...
Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Nevro Crop (NYSE:NVRO) on Wednesday, setting a price target of $210, which is approximately 34.43% above the...
This crisis has hit income-seekers—particularly retirees—hard. After the stomach-churning March selloff came the slashing of “sacred cow” dividends, like...
The convenience of a one-click ETF is tempting, but in times like these, buying one can seriously cap your upside—and cause you to leave serious dividend cash on the table,...
One stock that might be an intriguing choice for investors right now is Nevro Corp. (NYSE:NVRO) . This is because this security in the Medical - Instruments space is seeing solid...
Nevro Corp. is a global medical device company, which is focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Buy | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 75.35 | 76.28 | 73.55 | +0.15 | +0.20% | 84.70M | NASDAQ | |||
| 27.14 | 27.81 | 26.74 | -0.08 | -0.29% | 626.21K | NASDAQ | |||
| 178.30 | 179.44 | 177.41 | +0.16 | +0.09% | 5.33M | NYSE | |||
| 52.75 | 52.96 | 51.58 | +1.11 | +2.15% | 21.25M | NYSE | |||
| 170.70 | 171.95 | 169.48 | +1.69 | +1.00% | 4.20M | NASDAQ | |||
| 108.69 | 109.50 | 108.13 | -0.61 | -0.56% | 3.96M | NYSE | |||
| 117.43 | 122.28 | 113.37 | -2.80 | -2.33% | 1.84M | NYSE | |||
| 6.85 | 6.93 | 6.59 | -0.01 | -0.15% | 5.62M | NYSE | |||
| 45.23 | 46.28 | 43.74 | -0.31 | -0.68% | 3.18M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 0.94 | 0.988 | 0.91 | -0.0113 | -1.19% | 6.11M | NYSE | |||
| 0.127 | 0.1323 | 0.1201 | +0.0020 | +1.60% | 2.12M | NYSE | |||
| 97.68 | 98.65 | 96.18 | -0.29 | -0.30% | 1.00M | NYSE | |||
| 32.54 | 33.49 | 31.07 | -0.69 | -2.08% | 9.40M | NYSE | |||
| 172.73 | 175.06 | 170.83 | +0.53 | +0.31% | 3.94M | NYSE |